Skip to main content
Medicines, medical devices

Guidance and regulation

Skip to results
423 results sorted by Most viewed
  • Fees payable to the MHRA from 2025.

  • Take care when using creams to treat dry skin conditions as they can easily dry onto clothing, bedding and bandages, making them more flammable.

  • Guidance on the process for ending a clinical trial.

  • Guide for marketing authorisation holders, including qualified person responsible for pharmacovigilance (PV) and pharmacovigilance system master files (PSMF).

  • Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.

  • How to make a payment by credit or debit card or a bank transfer for all applications except Device Registration and Certificates of Free Sale applications.

  • How the MHRA makes decisions on whether a borderline product is a medical device and which risk class should apply.

  • How to use the procedure for medicines licensing applications.

  • This document provides guidance on the data integrity expectations that should be considered by organisations involved in any aspect of the pharmaceutical lifecycle or GLP studies regulated by MHRA.

  • Information to help comply with ICH guidelines, if you are running clinical trials in the UK.

  • Guidance for Applicants wishing to apply for a Promising Innovative Medicines designation, pre-submission meeting or an EAMS Scientific Opinion.

  • A digital platform designed to facilitate the reporting, monitoring, and management of medical device incidents.

  • How the MHRA processes variations to medicines' marketing authorisations for the UK and Northern Ireland.

  • How manufacturers should undertake a clinical investigation for a medical device to ensure they comply with medical device regulations.

  • Safety leaflet to help you understand the latest information about the effects of pregabalin during pregnancy.

  • You must get permission to export certain drugs and medicines.

  • A wholesale dealer in Great Britain may import Qualified Person certified medicines from the European Economic Area if certain checks are made by the ‘Responsible Person (import)’

  • By streamlining decision-making, the MHRA–NICE aligned pathway will help patients access new medicines 3–6 months sooner.

  • Information on the new regulations for the post-market surveillance of medical devices which come into effect on 16 June 2025.

  • Clinical trial applications that need expert advice from a specialist group or committee.